ResearchXOM
XOM — what the street is missing
Healthcare: XOM over 30 days — demo research by @fatima_alhariri.
Fatima Al-Hariri on XOM.
PhD pharmacology. I focus on PDUFA dates, trial readouts, and mispriced optionality in mid-cap biotech.
Thesis: long over 30 days. Entry locked at publication. Risk: macro shock overwhelms the single-name view.
[Demo seed content — not investment advice.]